Profile

Artenga’s microbubble drug conjugates (MDC) and focused ultrasound (FUS) are key enablers for:

  • Safe, non-invasive, targeted blood brain barrier drug delivery
  • Boosting immunotherapy efficacy without added toxicity
  • Our Sunnybrook collaborators did first clinical FUS and non-drug microbubble BBB opening for glioblastoma, Alzheimer’s, breast cancer, brain mets, ALS and Parkinson’s.

Differentiation factors are:

  • Higher dose delivered with greater perfusion
  • Liver clearance to mitigate systemic effects
  • AAV MDC and new tech planned to limit transduction to diseased brain regions
Artenga Inc. Logo

Website

www.artenga.com

Contact

Event details

Date: September 13 - 15, 2021

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

6 in total
  • Artenga Inc.
    Artenga’s microbubble drug conjugates (MDC) and focused ultrasound (FUS) are key…
  • KA Imaging
    KA Imaging has created color x-ray, which allows for early and more accurate diagnostics with higher radiology…
  • Mediphage Bioceuticals
    Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing a next-generation non-viral gene…
  • Nanology Labs
    Nanology Labs, a University of Toronto spin-off company, has developed a novel drug delivery platform technology…
  • Nucro-Technics
    Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both GLP…
  • Pocket MD
    PocketMD is a 24/7 healthcare marketplace that connects patients with doctors and allied health professionals…